The Role of JAK Inhibitors in Closing Gaps in RA Management

Modules 1-3

Program Overview

Research surrounding the targeted inhibition of intracellular tyrosine kinases that play a pivotal role in mediating proinflammatory responses and aberrant signaling pathways in RA has led to the development of the highly successful class of Janus kinase (JAK) inhibitors. However, as second-generation compounds become available, offering the potential for greater selectivity and improved safety profiles, important questions centering on their advantages, limitations, appropriate use, and implementation within the RA treatment algorithm remain. Further, lack of access to this class of agents persists as a common barrier to their appropriate use. In this multichannel, multiformat educational series—available in web, mobile, and downloadable/printable formats—3 expert rheumatologists will discuss the latest clinical trial evidence and current updates to national and international RA treatment recommendations specific to JAK inhibitor therapies. Additionally, experts will provide their unique perspectives on the translation of this evidence into best practices, offering insights into individualized patient management plans and actionable strategies for overcoming common barriers to RA care—all of which can be immediately implemented into same-day practice

This activity is jointly provided by Global Education Group and Integritas Communications.

 

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Image Webcast Series

credit amount 0.25

credit type CME/CE

expiration 09/24/2021

Image Webcast Series
Best Practices for Implementing JAK Inhibitors Into RA Management Plans

Module 2

Stanley B. Cohen, MD; Vibeke Strand, MD, MACR, FACR
MODULE 2
Begin Activity

credit amount 0.50

credit type CME/CE

expiration 09/24/2021

Image Webcast Series
Overcoming Access Barriers to RA Treatment: The “How-to”

Module 3

Stanley B. Cohen, MD; Madelaine A. Feldman, MD, FACR; Vibeke Strand, MD, MACR, FACR
MODULE 3
Begin Activity

credit amount 0.25

credit type CME/CE

expiration 09/24/2021

Resource

The Role of JAK Inhibitors in Closing Gaps in RA Management